FDA-cleared profile

TumorSight Viz

SimBioSys, Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.

Clinical role
Visualization, segmentation, and measurement support
Images and patients
MRI · Breast
Key limitation
Keep in mind: The output supports visualization and analysis but patient-management decisions should not be made solely from TumorSight Viz results.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Breast Input: Dynamic contrast-enhanced breast MRI DICOM studies from patients with biopsy-proven invasive early-stage or locally advanced breast cancer; the FDA packet describes manual or automated DICOM import.
  • Who uses it?Intended users: Skilled physicians and clinicians, including radiologists, interpreting breast MRI
  • What does the software produce?Output: Registered and subtracted images, MIPs, reformats, kinetic curves, parametric maps, 3D tumor segmentation, tumor volume, tumor-to-breast ratio, longest dimension, tumor-to-nipple/skin/chest distances, and center of mass.
  • What is its most important limitation?Key limitation: The output supports visualization and analysis but patient-management decisions should not be made solely from TumorSight Viz results.

Clinical takeaway. Clinical role: TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.

Evidence takeaway. Evidence from the reviewed source record: Validation used 267 samples from 266 patients at more than eight U.S. sites, with pathologically confirmed invasive breast cancer and reference measurements from three board-certified radiologists.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction, segmentation, 3D renderings, measurements, kinetic curves, parametric maps, MIPs, and reformats for physician visualization and analysis; results are not the sole basis for patient management.
  • Exact FDA submission
  • Checked 2026-09-06
Workflow role
Visualization, segmentation, and measurement support
  • Exact FDA submission
  • Checked 2026-09-06
Required input
Dynamic contrast-enhanced breast MRI DICOM studies from patients with biopsy-proven invasive early-stage or locally advanced breast cancer; the FDA packet describes manual or automated DICOM import.
  • Exact FDA submission
  • Checked 2026-09-06
Output and clinician action
Registered and subtracted images, MIPs, reformats, kinetic curves, parametric maps, 3D tumor segmentation, tumor volume, tumor-to-breast ratio, longest dimension, tumor-to-nipple/skin/chest distances, and center of mass.
  • Exact FDA submission
  • Checked 2026-09-06
Care setting
Adult breast oncology imaging for biopsy-proven early-stage or locally advanced breast cancer
  • Exact FDA submission
  • Checked 2026-09-06
Intended users
Skilled physicians and clinicians, including radiologists, interpreting breast MRI
  • Exact FDA submission
  • Checked 2026-09-06
Limitations
The output supports visualization and analysis but patient-management decisions should not be made solely from TumorSight Viz results.
  • Exact FDA submission
  • Checked 2026-09-06
Evidence summary
Validation used 267 samples from 266 patients at more than eight U.S. sites, with pathologically confirmed invasive breast cancer and reference measurements from three board-certified radiologists.
  • Exact FDA submission
  • Checked 2026-09-06

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Validation used 267 samples from 266 patients at more than eight U.S. sites, with pathologically confirmed invasive breast cancer and reference measurements from three board-certified radiologists.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Tumor volume mean absolute error

5.2 cc

  • EndpointTumor volume agreement with radiologist reference
  • PopulationBreast MRI validation subset
  • Tested versionTumorSight Viz submitted in K251766; build not stated

Segmentation volumetric Dice

0.76 Dice

  • EndpointTumor segmentation overlap
  • PopulationBreast MRI validation subset
  • Tested versionTumorSight Viz submitted in K251766; build not stated

Segmentation surface Dice

0.92 Dice

  • EndpointTumor segmentation surface overlap
  • PopulationBreast MRI validation subset
  • Tested versionTumorSight Viz submitted in K251766; build not stated

TumorSight Viz breast MRI measurement and segmentation validation

  • DesignRetrospective multicenter validation against radiologist reference measurements
  • Population267 samples from 266 patients with pathologically confirmed invasive early-stage or locally advanced breast cancer; MRI from GE, Philips, and Siemens 1.5T and 3T systems
  • Scopeexact submission
  • Tested versionTumorSight Viz submitted in K251766; build not stated
  • Samplen=267
  • IndependenceIndependence not established

K251766

Three board-certified radiologists established reference measurements; the FDA packet states more than eight U.S. sites.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Dynamic contrast-enhanced breast MRI DICOM studies from patients with biopsy-proven invasive early-stage or locally advanced breast cancer; the FDA packet describes manual or automated DICOM import.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-06 · FDA 510(k) K251766: TumorSight Viz

  2. Routing

    Source context, not route validation: The device reads DICOM MRI and displays results in the TumorSight web application; image import can be manual or automated and results are accessed through an off-the-shelf computer.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-06 · FDA 510(k) K251766: TumorSight Viz

  3. AI processing

    Source context, not route validation: The exact FDA package describes TumorSight software hosted on a cloud-based platform and accessed on an off-the-shelf computer, with results processed and displayed on the TumorSight web application. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer." … "TumorSight reads DICOM magnetic resonance images. TumorSight processes and displays the results on the TumorSight web application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA 510(k) K251766: TumorSight Viz

  4. Returned objects

    Source context, not route validation: Registered and subtracted images, MIPs, reformats, kinetic curves, parametric maps, 3D tumor segmentation, tumor volume, tumor-to-breast ratio, longest dimension, tumor-to-nipple/skin/chest distances, and center of mass.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-06 · FDA 510(k) K251766: TumorSight Viz

  5. Viewer/worklist/report

    Unresolved route: Registered and subtracted images, MIPs, reformats, kinetic curves, parametric maps, 3D tumor segmentation, tumor volume, tumor-to-breast ratio, longest dimension, tumor-to-nipple/skin/chest distances, and center of mass.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-06 · FDA 510(k) K251766: TumorSight Viz

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes TumorSight software hosted on a cloud-based platform and accessed on an off-the-shelf computer, with results processed and displayed on the TumorSight web application. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The TumorSight system consists of proprietary software developed by SimBioSys, Inc. hosted on a cloud-based platform and accessed on an off-the-shelf computer." … "TumorSight reads DICOM magnetic resonance images. TumorSight processes and displays the results on the TumorSight web application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The device reads DICOM MRI and displays results in the TumorSight web application; image import can be manual or automated and results are accessed through an off-the-shelf computer.
  • Exact FDA submission
  • Checked 2026-09-06

Web and DICOM workflow

The exact submission describes manual or automated DICOM import, cloud-based processing, and display in the TumorSight web application on an off-the-shelf computer.

exact submission · checked 2026-09-06

Current family visualization workflow

SimBioSys describes TumorSight Viz as DCE-MRI software with 3D visualization, auto-segmented tumor/anatomical structures, and measurements; its prone-to-supine feature is explicitly described as research-use only.

product family · checked 2026-09-07

Current family page is not used to promote unvalidated features into the exact K251766 performance record.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K251766
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-06
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-07-08
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-07Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public amount, range, currency, geography, or contract term was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "SimBioSys TumorSight reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-07 - Exact FDA submission

    No scoped current security or data-flow documentation was established.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-07 - Exact FDA submission

    Current onboarding, competency, and support commitments were not established.

  • Monitoring: Not verified - checked 2026-09-07 - Exact FDA submission

    Local acceptance testing, production monitoring, update control, and drift review were not established.

7 sources - 3 history items

Source ledger

  1. FDA 510(k) K251766: TumorSight Viz

    U.S. Food and Drug Administration - Published 2025-07-08 - Accessed 2026-09-06

    Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, deployment, evidenceSummary, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TumorSight Viz model card (K251766)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. TumorSight Viz official product page

    SimBioSys - Accessed 2026-09-07

    Scope: productFamilyWorkflow, implementationCapabilities

Research history

  1. K251766 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-authorized DEN170022

QuantX

Quantitative Insights, Inc

Authorized purpose: QuantX is breast MRI software for the labeled management, analysis, visualization, and decision-support workflow; exact image inputs, outputs, and use remain submission-specific.

Modality
MRI
Anatomy
Breast
Decision
2017-07-19
FDA-cleared K243189

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: Visualize and analyze DCE breast MRI studies for patients with biopsy-proven early-stage or locally advanced breast cancer, including processing, measurements, and configurable finding visualization; results are not a sole basis for patient management.

Modality
MRI
Anatomy
Breast, including biopsy-proven breast tumors/findings.
Decision
2024-10-25
FDA-cleared K231130

TumorSight Viz

SimBioSys, Inc.

Authorized purpose: TumorSight Viz analyzes dynamic contrast-enhanced breast MRI for visualization and analysis of biopsy-proven early-stage or locally advanced breast cancer, including registration, subtraction, measurements, and three-dimensional views to support physician review.

Modality
MRI
Anatomy
Breast; early-stage or locally advanced breast cancer
Decision
2023-12-26
FDA-cleared K253413

LiverMultiScan (v6.0)

Perspectum, Ltd.

Authorized purpose: LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Modality
MRI
Anatomy
Liver
Decision
2026-03-09

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history